AI Article Synopsis
- The J-valve system was used for valve-in-valve implantation to treat tricuspid bioprosthetic structural valve degeneration (SVD) in two high-risk male patients, aged 46 and 67.
- Both procedures were successful, with no complications during a 12-month follow-up, and patients experienced no traces of tricuspid regurgitation.
- The study concludes that the ViV technique with J-valve is an effective alternative for high-risk patients, minimizing the need for more invasive surgical options.
Article Abstract
Background: Patients with tricuspid bioprosthetic structural valve degeneration (SVD) often present with right ventricular enlargement and severe dysfunction, which cause a higher risk for redo cardiac surgery. In 2019, our center innovated using the J-valve system for valve-in-valve (ViV) implantation to treat tricuspid bioprosthetic SVD. The purpose of this study was to summarize the clinical effect after 1-year follow-up.
Case Description: From April 2019 to October 2019, two cases of tricuspid bioprosthetic dysfunction were treated with the J-valve system. Both patients were male, aged 46 and 67 years, respectively. The preoperative evaluation showed that the risk of conventional redo open heart surgery was high. The J-valve implantation was successful in both cases. One patient had slight valve displacement when the transporter was withdrawn during the operation, and a second J-valve was implanted in an ideal position. There was no death, no delayed valve displacement, and no readmission during the follow-up period of 12 months. In both cases, there was an absence of trace tricuspid regurgitation. After 6 months of anticoagulation with warfarin, the patients were converted to long-term aspirin treatment.
Conclusions: The ViV technique with J-valve is feasible and effective in treating tricuspid bioprosthetic SVD in high-risk patients, avoiding cardiopulmonary bypass and conventional thoracotomy injury.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944779 | PMC |
| http://dx.doi.org/10.21037/jtd-23-1961 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 21-year-old man, known case of the repaired congenital heart disease, developed complete atrioventricular block (AVB) one week after simultaneous bioprosthetic pulmonary and tricuspid valve replacement and atrial septal defect repair. Considering the persistence of the AVB, it was decided to implant a permanent pacemaker. After considering all available options and the issues related to the patient, it was decided to implant a leadless pacemaker (LLP).
View Article and Find Full Text PDFComplete heart block and subsequent sudden cardiac death following transcatheter tricuspid valve replacement in a heart transplant patient: a case report.
Eur Heart J Case Rep
December 2024
Department of Medicine, Western University, London, ON N6A 5W9, Canada.
Article Synopsis
- Tricuspid regurgitation (TR) is a common issue after heart transplantation, and a new treatment called transcatheter tricuspid valve replacement (TTVR) has emerged, although it comes with risks.
- A 46-year-old woman who underwent a heart transplant developed severe TR, had a TTVR procedure, but later suffered from cardiogenic shock and sudden cardiac death, linked to complications in the area of her heart's electrical conduction system.
- This case highlights the dangers of TTVR in heart transplant patients, emphasizing the need for close monitoring due to the potential for serious heart rhythm issues like complete heart block.
Tricuspid valve replacement with mechanical versus biological prostheses: a systematic review and meta-analysis.
J Cardiothorac Surg
November 2024
Department of Surgery, Division of Pediatric and Adult Congenital Cardiac Surgery, Maria Fareri Children's Hospital, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY, 10595, USA.
Background And Objective: Tricuspid valve replacement (TVR) is required when repair is not feasible, and it continues to be a relatively high-risk procedure owing to the complex medical and/or surgical profile of patients. The choice between mechanical and biological prostheses for TVR remains a subject of debate owing to their distinct advantages and disadvantages. This study aimed to analyse and compare the clinical outcomes of these two types of prostheses in the tricuspid position.
View Article and Find Full Text PDFDurability of porcine and pericardial prostheses in tricuspid valve replacement.
JTCVS Open
October 2024
Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, NC.
Article Synopsis
- The study compares the survival rates and durability between porcine and pericardial prostheses used in tricuspid valve replacement over a period from 1975 to 2022.
- Results show no significant differences in 10-year survival rates, cumulative incidence of structural valve deterioration, or reoperation rates between the two types of valves.
- The findings suggest that both valve types are equally effective, indicating that the choice of valve may be based on other factors rather than survival or durability outcomes.
Prosthetic Valve Fate in Patients With Continuous-Flow Left Ventricular Assist Devices.
ASAIO J
November 2024
From the Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York.
Prosthetic valve-related morbidity and mortality in patients with left ventricular assist devices (LVADs) remain unclear. We retrospectively reviewed patients who received a HeartMate II or 3 LVAD at our center between April 2004 and December 2022. Patients with a valve prosthesis in any position were included.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!